portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


  Fosun Pharma Buys 70% of Jinzhou Ahon Pharma for $219 Million
 
CreateTime:2011-09-14 Editor:lile
Text Size:       
 

Shanghai Fosun Pharmaceutical (Group) (600196.SH) will pay up to $219 million to acquire a 70% stake in Jinzhou Ahon Pharmaceutical Co. Shanghai Fosun said the acquisition will make its drug portfolio more competitive, especially in Ahon’s core strengths of the cardiovascular and central nervous system sectors.

Fosun Pharma also announced it will form a generic drug JV with Lonza Group of Switzerland, backed by $15.6 million in capital. The JV will take advantage of the strengths of each parent: Lonza in APIs and intermediates; Fosun in finishing and China distribution. The JV will be owned equally by the two partners.

 


Related Reports
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
Global and China Monoclonal Antibody Industry Report, 2019-2025
China Contract Research Organization (CRO) Industry Report, 20...
2005-2010 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1